http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2747386-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 |
| filingDate | 2016-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c77b2323e1cc5000d5b8a18cc89fa93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89b8fea71f9f474816dd8b5108ddd930 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28c1771c7658fd098f447b769f41224f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbed67562f30a2d081a26772f360ab82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2e4f29600f89e2435569888d33ac9ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2a3d60a6d44931bf46ddf2879058bb8 |
| publicationDate | 2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2747386-T3 |
| titleOfInvention | Heteroarylene-linked benzodiazepine dimers, conjugates thereof and methods of preparation and use |
| abstract | A benzodiazepine dimer having a structure represented by formula (I) ** Formula ** wherein X is selected from the group consisting of ** Formula ** and ** Formula ** R1 is in accordance with the formula (la) or formula (Ib): ** Formula ** or each G and G 'is C or N, provided that no more than two G or two G' are N; each R2 is independently H or C1-C5 alkyl; each R3 and R4 is independently H, F, Cl, Br, OH, C1-C3 alkyl, O (C1-C3 alkyl), cyano, (CH2) 0-5NH2 or NO2; each double line in a diazepine ring system independently represents a single bond or a double bond; each R5 is H if the double line to which it is attached is a single bond and is absent if the double line is a double bond; each R6 is H, OH, SO3Na or SO3K if the double line to which it is attached is a single bond and is absent if the double line is a double bond; each R7, R8, R9 and R10 is independently H, C1-C5 alkyl, C≡C (CH2) 1-5X2, OH, O (C1-C5 alkyl), cyano, NO2, F, Cl, Br, O (CH2CH2O ) 1-8 (C1-3 alkyl), (CH2) 0-5X2, O (CH2) 2-5X2, 3- to 7-membered cycloalkyl or heterocycloalkyl unsubstituted or substituted with (CH2) 0-5X2 or O (CH2) 2-5X2, 5- to 6-membered aryl or heteroaryl unsubstituted or substituted with (CH2) 0-5X2 or O (CH2) 2-5X2, or or where a R7, R8, R9 or R10 is attached to a G or G ' which is N, such as R7, R8, R9 or R10 is absent; dotted lines in ring C of formula (Ib) indicate the optional presence of a C1-C2, C2-C3 or C2-R11 double bond; R11 is H, = O, = CH2, = CH (C1-C5 alkyl), CH = CH (CH2) 1-5X2, C≡C (CH2) 1-5X2, C1-C5 alkyl, OH, O (C1 alkyl -C5), cyano, NO2, F, Cl, Br, O (CH2CH2O) 1-8 (C1-3 alkyl), (CH2) 0-5X2, 4- to 7-membered aryl, unsubstituted heteroaryl, cycloalkyl or heterocycloalkyl or substituted with (CH2) 0-5X2, O (CH2) 2-5X2, unsubstituted 3- to 7-membered cycloalkyl or heterocycloalkyl or substituted with (CH2) 0-5X2 or O (CH2) 2-5X2, aryl or heteroaryl of 5 to 6 members unsubstituted or substituted with (CH2) 0-5X2 or O (CH2) 2-5X2; R11 'is absent if a C1-C2, C2-C3 or C2-R11 double bond is present and is H otherwise; each X2 is independently H, F, Cl, Br, OH, O (C1-C3 alkyl), O (C1-C3 alkylene), CO2H, N3, CN, NO2, CO2 (C1-C3 alkyl), NH2, NH ( C1-C5 alkyl), N (C1-C5 alkyl) 2, SH, CHO, N (CH2CH2) 2N (C1-C3 alkyl), NHNH2 or C (= O) NHNH2; each Y is independently CH2, C = O, or CHR12; wherein each R12 is independently F, Cl, Br, or C1-C3 alkyl; and Y 'and Y "are independently CH2, C = O, or CHR12; wherein each R12 is independently F, Cl, Br, or C1-C3 alkyl, provided that at least one of Y' and Y" is present; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2015-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 396.